DELAWARE DEPARTMENT OF HEALTH AND SOCIAL SERVICES: $117M Department of Health and Human Services Grant
Summary
The Delaware Department of Health and Social Services received a $117M State Opioid Response grant from HHS/SAMHSA to combat opioid and stimulant use disorder. As the recipient is a state agency and not a publicly traded company, there is no direct market impact from this award. The spending signals continued federal commitment to opioid crisis mitigation but does not directly benefit any public company.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.$117M federal grant to Delaware for opioid response, but recipient is state agency, not public company.
- 2.No publicly traded tickers are affected; avoid speculative supply chain guesses.
- 3.Federal opioid spending continues but does not directly impact stock market without identifiable public beneficiaries.
Market Implications
This contract does not directly affect any publicly traded company. Investors should not interpret this award as a catalyst for healthcare or substance abuse treatment stocks unless further subcontract awards to public firms are disclosed. The broader sector trend of increased federal spending on opioid response may support healthcare service providers over time, but no specific ticker benefits from this award alone.
Full Analysis
The contract is a $117M project grant awarded to the Delaware Department of Health and Social Services (DHSS) by the Substance Abuse and Mental Health Services Administration (SAMHSA), an agency within the Department of Health and Human Services. The grant funds Delaware's State Opioid Response (SOR) 4.0 project, a statewide initiative to enhance opioid and stimulant use disorder care, focusing on key populations including pregnant people, racial minorities, justice-involved individuals, LGBTQ+ individuals, and youth. The three-year grant will provide treatment, recovery, prevention, and harm reduction services across Delaware.
Since the recipient is a state government entity, there is no publicly traded parent company or direct beneficiary. The contract does not flow through a public company, so no tickers can be assigned. Supply chain partners or competitors would be speculative; the instructions explicitly warn against guessing private-entity supply chains to avoid false positives.
No related legislation from the provided bill signals directly authorizes or appropriates this specific grant. While some bills touch on healthcare (e.g., S5006 - Work Without Worry Act), none share a specific objective or mechanism with this opioid response grant. The connection to legislation is therefore absent.
Historical patterns show that state-level opioid response grants are typically renewed and can grow over time, but they do not create direct revenue streams for publicly traded companies unless a specific vendor contract is awarded. In this case, no such vendor is identified.
Market implications are minimal as the award is to a state government. The opioid crisis remains a public health priority, but investors should not expect stock price movements from this contract alone.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DEPARTMENT OF HUMAN SERVICES HAWAII: $2.2B Department of Health and Human Services Grant
KANSAS DEPARTMENT OF HEALTH & ENVIRONMENT: $4.6B Department of Health and Human Services Grant
NEW MEXICO HEALTH CARE AUTHORITY: $9.4B Department of Health and Human Services Grant
HEALTH SERVICES KENTUCKY CABINET FOR: $18.2B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.1B Department of Health and Human Services Federal Award
ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM: $19.6B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
HEALTH CARE SERVICES, CALIFORNIA DEPARTMENT OF: $6.2B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Contract Details
Recipient
DELAWARE DEPARTMENT OF HEALTH AND SOCIAL SERVICES
Award Amount
$116,780,447
Awarding Agency
Department of Health and Human Services
Sub-Agency
Substance Abuse and Mental Health Services Administration
Contract Type
PROJECT GRANT (B)
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →